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Key Points
• A novel FXI binding tripeptide
motif has sequence Asp-Phe-
Pro (DFP).
• FXI complex crystal struc-
tures reveal DFP
peptides bound to the apple
2 domain.
Factor XI (FXI) is the zymogen of FXIa, which cleaves FIX in the intrinsic pathway of
coagulation. FXI is known to exist as a dimer and interacts with multiple proteins via its 4
apple domains in the “saucer section” of the enzyme; however, to date, no complex
crystal structure has been described. To investigate protein interactions of FXI, a large
random peptide library consisting of 106 to 107 peptides was screened for FXI binding,
which identified a series of FXI binding motifs containing the signature Asp-Phe-Pro
(DFP) tripeptide. Motifs containing this core tripeptide were found in diverse proteins,
including the known ligand high-molecular-weight kininogen (HK), as well as the
extracellular matrix proteins laminin and collagen V. To define the binding site on FXI,
we determined the crystal structure of FXI in complex with the HK-derived peptide
NPISDFPDT. This revealed the location of the DFP peptide bound to the FXI apple 2 domain, and central to the interaction, the DFP
phenylalanine side-chain inserts into amajor hydrophobic pocket in the apple 2 domain and the isoleucine occupies a flankingminor
pocket. Two further structures of FXI in complexwith the laminin-derived peptide EFPDFP and aDFPpeptide from the randomscreen
demonstrated binding in the same pocket, although in a slightly different conformation, thus revealing some flexibility in the
molecular interactions of the FXI apple 2 domain. (Blood. 2016;00(00):1-9)
Introduction
The physiological function of coagulation factor XI (FXI) is poorly
understood compared with the vitamin K–dependent coagulation
proteases; people deﬁcient in FXI do not show the strong bleeding
phenotypes observed for FVIII and FIX deﬁciency.1 From a structural
perspective, FXI is unique among the coagulation factors because it
circulates as a disulﬁde-linked dimer.2-4 Each subunit has 607 amino
acids,with four 90–aminoacid apple domains (A1-A4) that, in the FXI
monomer, assemble into a saucer-shaped disc, with the protease
domain restingon top inan arrangement thatwehavedescribedas a cup
and saucer.5 Biochemical data have mapped protein interactions to the
appledomains for diverse ligands, including substrate FIX,6 thrombin,7
platelet glycoprotein Ib,8 and high-molecular-weight kininogen (HK),9
but to date, no complex crystal structures have been determined
to deﬁne the molecular basis of these interactions.10 FXI circulates
in complex with cofactor HK.9 A close homolog of FXI is plasma
coagulation factor prekallikrein (PK), which has the same domain
structure, with 4 apple domains at the N-terminus. In common with
FXI, PK also binds HK, but unlike FXI, PK is a monomeric protein.11
The 2 pathways contributing to blood coagulation in humans are the
intrinsic pathway, which can be activated by FXIa cleaving FIX, and
the extrinsic pathway, which is activated by tissue factor. In addition to
the principal substrate FIX, FXIa has also been shown to cleave and
inactivate tissue factor pathway inhibitor, promoting a pathway of
intravascular thrombus formation.12 Several lines of evidence suggest
that therapeutic intervention targeting FXI andHK has the potential for
providing medicines with a safer anticoagulation proﬁle than those
currently available.1,13,14
Randomcombinatorial peptide libraries based on theone-bead-one-
compound method have proved successful in identifying ligands for
various macromolecular targets.15 By screening a random peptide
library comprising 106 to 107 peptides, we have identiﬁed FXI binding
peptides that all share the core motif Asp-Phe-Pro (DFP). Of im-
portance, this motif can also be found in the cofactor HK, laminin, and
collagen V. By determining 3 FXI-DFP peptide ligand complex
structures, we show how synthetic DFP peptides interact with a pocket
in the apple 2 domain and how the dimeric FXI orients 2 bound DFP
peptides onto the same surface.
Methods
Synthesis and screening of peptide libraries
The one-bead-one-compound libraries were synthesized on TentaGel S-NH2
resin (Rapp Polymere, Tu¨bingen, Germany Q:3) using the split-mix method.15,16
Two unbiased libraries (libraries 1 and 2) where screened against biotinylated
FXI. Library 1 was ﬁxed at 12 residues in length; library 2 had varying lengths.
The format for library 1was O12-resin, wherebyOwasD,N,2Q,A,S,T,G,P,H,K,
R,Y,W,F,L,I,V and M and C were omitted. The format for library 2 was
OO-C-O0,1,2-C-O0,1,2-C-O0,1,2-C-OO-resin,wherebyOwasD,N,E,Q,A,S,T,G,
P,H,K,R,VandC (onlyhydrophobic)wasW,F,Y,L,V; the residuesMandCwere
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omitted.A total of 1 g of resinwas used in a 5-mL syringewithﬁlter frit. The resin
was washed 5 times with 15 mM Tris pH 7.4, 150 mM sodium chloride (NaClQ:4 ),
0.5% bovine serum albumin, and 0.05% Tween 20 (incubation buffer). For
prescreening of libraries against streptavidin-alkaline phosphatase (Strep-AP;
stock 1mg/mL; Sigma), Strep-APalonewas added to the library to aﬁnal dilution
of 1:10 000 and incubated for 30 minutes. This library was then washed 4 times
with washing buffer (15 mM Tris pH 7.4, 150 mMNaCl, and 0.05% Tween 20)
and washed twice with staining buffer (50mMTris pH 8.8, 0.15MNaCl, 0.05%
Tween 80, and 15 mM magnesium chloride). The substrate 6-chloro-3-indoxyl-
phosphate (50mg/mL inN-methyl-2-pyrrolidone; Biosynth AG) was added, and
the reactionwas allowed toproceed for 30 to45minutes. For screeningof libraries
against FXI, the resinswerewashedwith 6Mguanidinium chloride pH 3.0 for 20
minutes, washed with washing buffer, and lastly washed twice with incubation
buffer. Biotinylation of FXI was performed using 200mg of FXI, which was gel
ﬁltrated using a NAP5 column equilibrated with 1% sodium bicarbonate pH 8.
Added to this solution (500 mL) was 4 mL of a 7 mM solution of biotin
N-hydroxysuccinimide ester (Sigma) in DMSO, and the reactionwas allowed
to proceed for 3 hours at 4°C. The FXIwas then gel ﬁltrated using aNAP5 column
against 100 mM NaCl and Tris buffer pH7.4 and stored in aliquots (30 mL) at2
25°C. A total of 4 mL of biotinylated FXI (stock concentration 1.2 mM) plus 1
mL of Strep-AP was added to the library in 2 mL of incubation buffer and allowed
to incubate for 2 hours. The resin was washed 3 times with washing buffer and
then staining buffer, and 5-bromo-4-chloro3-indolyl phosphate with nitro blue
tetrazoliumwas added. After 1 hour, the reactionwas stopped and themost intense
blue beads were removed for sequencing. For the sequence determination,
blue beads were removed under a microscope and sequenced by an Edman
sequencer (Procise, Applied Biosystems). Peptide sequences were aligned
using the programMEME17 to produce Figure 1B, and database searches for
DFP motifs were performed using PROSITE.18 In Figure 3A, HK protein
sequences were aligned with National Center for Biotechnology Information
HOMOLOGENE server, and the shaded were aligned with the BOXSHADE
server. Q:5
Protein crystallization and structure determination
Recombinant human untagged FXI was expressed and puriﬁed from CHO Q:6
cells as previously described.19 All synthetic peptides used for crystallization
experiments were purchased fromGenScript. FXI was concentrated to 8mg/mL
and added to an equal volume of peptide sequence YPRHIYPDFPTDTT (P39),
FNPISDFPDTTS (HKP), and RLEFPDFPIDD (LP2) to achieve a 1:5 protein-
to-peptide molar ratio for P39 and a 1:6 ratio for peptides HKP and LP2. The
resulting solution was 4 mg/mL FXI in 50 mM Tris-HCl pH 7.6 and 75 mM
NaCl. Crystals were grown in sitting drop from conditions of 0.1 M 2-(N-
morpholino)ethanesulfonic acid pH 6.5 and 20% polyethylene glycol 4000 for
the FXI-P39 complex and 0.1 M N-2-hydroxyethylpiperazine-N9-2-ethanesul-
fonic acid pH 7.5 and 20% polyethylene glycol 1500 for the FXI-HKP and FXI-
LP2 complexes. Data were collected from 2 crystals for FXI-P39 and on a single
crystal for FXI-HKP and FXI-LP2 at the Diamond Light Source synchrotron
usingbeamline I04.Datawere processedwithXDS20 and reduced in spacegroup
P43212 using the CCP4 software suite
21 (Table 1). The structures were solved by
molecular replacement using Phaser,22 with the crystal structure of FXI
(ProteinData Bank code 2F83)5 as a searchmodel. High-quality 2mFo2DFc
and mFo 2 DFc Q:7electron density maps enabled direct location of the bound
peptides (supplemental Figure 2, available on the Blood Web site). Manual
rebuilding was performed using the program Coot,23 and reﬁnement was
performedusingREFMAC,with statistics shown inTable1.Protein structures in
Figures 2A-B,D,F and4weregeneratedusingPyMOL,and those inFigure 2C,E
used LIGPLOT.24
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Figure 1. FXI binding peptides with the DFP motif.
(A) Alignment of peptide sequences from the random
screen, with 52Q:19 peptides shown containing the DFP
tripeptide. (B) Peptide motif overview calculated using
MEME software for the 52Q:20 FXI-binding DFP peptide
sequences. (C) Location of DFP pentapeptide se-
quences in the proteins HK (KNG1_HUMAN), laminin
(LAMA1_HUMAN), and collagen V (CO5A1_HUMAN)
identified using PROSITE softwareQ:21 .
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SPR binding studies
Plasma-puriﬁed HK was purchased from Enzyme Research Laboratories.
Laminin 111, 411, and 511were purchased fromBioLamina. HK, FXI, or laminin
was immobilized onto a CM5 chip using an amine coupling kit (GE Healthcare),
andexperimentswere performedonaBiacore 3000 instrument.The runningbuffer
used for all experiments was 10 mM N-2-hydroxyethylpiperazine-N9-2-
ethanesulfonic acid pH7.5, 140mMNaCl, 5mMETDA, and 0.005%polysorbate
20.Toassessanynonspeciﬁcbinding, theanalyte (FXIorpeptide)wasalso injected
over an empty ﬂow cell. Collagen V peptide sequence KDLQLCHPDFPDGEB
and HK peptide sequence INPTTQMKESYYFDLTDGLS (HKC) were
purchased from Biomatik. Binding curves were analyzed on the basis of the
surface plasmon resonance (SPR) response units recorded at equilibrium for
each analyte protein concentration, and a Hill plot was generated using Prism
6 (GraphPad Software). Competition assays were performed with increasing
concentrations of peptide P39 (6-600 nM)mixedwith aﬁxed concentration of
FXI (6 nM).
Results
Identification of peptides binding FXI
To identify peptides and novel ligands for FXI, we screened a random
peptide library containing greater than 3million peptides and identiﬁed
52FXIbindingpeptides.From the sequences identiﬁed (termedP1-P52),
37 were observed to contain the tripeptide motif Asp-Phe-Pro (DFP)
and 4 others contained a related DFD sequence, 2 DFS sequences,
or a single DLP sequenceQ:8 . Figure 1A shows the DFP-containing
peptides aligned, and supplemental Figure 1 contains all 52 peptide
sequences. A hydrophobic side chain F/Y/I/W located 2 amino acids
before DFP is preferred across all DFP peptides, with the exception
of HxDFP, and there are no examples in which a charged K/R/D/E
amino acid occupies this position. The most common motif is
F/YxDFP, present in 29 peptides; 3 peptides contain IxDFP and 2
containWxDFP or HxDFPQ:9 . A preference for proline occurs between
F/Y/I and the DFP tripeptide, with the second preference being
an acidic residue. It is also common to observe 1 or 2 basic residues
N-terminal to the hydrophobic F/Y/I/W residue. By contrast, the
C-terminus does not show any conserved features, and several
peptides have no residues present C-terminal to the DFP motif.
A searchof theSwiss-Prot database for extracellular humanproteins
containing the DFP motif revealed that the FxDFP sequence occurs in
13 human proteins, YxDFP in 4, HxDFP in 3,WxDFP in 2, and IxDFP
in 7 (supplemental Tables 1-3). The known binding partner for FXI
(cofactor HK)25 contains the sequence ISDFP (residues 585-589; ma-
ture sequence numbering is used from the Swiss-Prot database entry
name KNG1_HUMAN), which is located in the C-terminal domain 6.
Other proteins that contained aclosematch to sequences from the screen
include the extracellular matrix protein laminin a1 chain, with the
sequence YRDFP (sequence LAMA1_HUMAN, residues 1081-1085,
termed LP1) and FPDFP (residues 2191-2195, termed LP2). The
laminin peptideLP2most closely resembles the screen peptides,with
FPDFP being the most common pentapeptide motif occurring in
8 peptides. Other proteins that closely match the pentapeptide
preferences include matrix protein collagen V, with the sequence
HPDFP (sequence CO5A1_HUMAN, residues 1646-1650) and
collagen XI (sequence COBA1_HUMAN, residues 1614-1618)
(Figure 1C).
Structures of F/YxDFP peptide FXI complexes
We next synthesized examples of peptides containing the DFP motif,
including peptide P39 from the screen and DFP peptides derived from
HK (HKP) and laminin (LP2), and performed cocrystallization
experimentswithFXI. The laminin-derivedLP2 peptidewith sequence
RLEFPDFPIDD cocrystallized with FXI in a 1:6 molar mixture, and
the structure was solved to 3.0 A˚ resolution, with clearly identiﬁable
electron density for the sequence EFPDFP. The peptide forms contacts
exclusively with the apple 2 domain through interactions with a major
and minor pocket, burying a total surface area of 992 A˚2 (Figure 2A).
Table 1. Crystallographic data collection and refinement statisticsQ:25
FXI-HKP FXI-P39 FXI-LP2
Data collection
Space group P43212 P43212 P43212
Cell dimensions
a, b, c subunit, A˚ 80.6, 80.6, 251.8 81.3, 81.3, 252.2 81.1, 81.1, 253.0
a, b, g subunit, ° 90, 90, 90 90, 90, 90 90, 90, 90
Resolution, A˚ 39.8-2.85 (2.92-2.85) 77.41-2.80 (2.90-2.80) 77.32-3.0 (3.08-3.0)
Rsym* 0.083 0.094 0.158
I/sigI 16.0 (3.0) 17.1 (2.8) 12.5 (3.1)
Completeness, % 99.9 (100.0) 95.1 (71.9) 97.78 (97.2)
Redundancy 6.0 (6.2) 8.3 (3.5) 9.8 (9.1)
Refinement
Number of reflections 20 319 19 565 23 419
Rwork /Rfree† 0.226/0.285 0.201/0.264 0.210/0.279
B-Q:26 factors, A˚2
Protein 81.5 74.6 80.30
Ligands 21.0 111.80 117.50
Root mean square deviationsQ:27
Bond lengths, A˚ 0.011 0.015 0.022
Bond angles, ° 1.82 1.82 1.98
Protein Data Bank code 5I25 5EOK 5EOD
Values in parentheses are for highest-resolution shell.
*Rsym is Sum(h) [Sum(j) [I(hj)2,Ih.]/Sum(hj), Ih., where I is the observed intensity and,Ih. is the average intensity of multiple observations from symmetry-related
reflections calculated with SCALA.
†Rwork is Sum(h) ||Fo|h 2 |Fc|h|/Sum(h) |Fo|h, where Fo and Fc are the observed and calculated structure factors, respectively. Rfree is computed as in Rwork, but only for
(5%) randomly selected reflections, which were omitted in refinement, calculated using REFMACQ:28 .
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Central to the interaction is the DFP phenylalanine side chain that ﬁts
precisely into a major pocket, forming contacts with side chains from
the apple domain b sheet (residues Leu148, Ile146, Thr132, and
Ala134). The DFP proline ring packs against the His143 side chain
from the b4-b5 loop. The DFP aspartate side chain forms a salt bridge
to FXI Lys103 and a hydrogen bond to the FXI Asn106 side chain
(Figure 2A). A second interaction site occurs from the peptide phenyl-
alanine that isQ:10 2 residues N-terminal to theDFP side chain, contacting a
minor pocket formed by residuesTyr107,Asn108, andSer109. For this
peptide, the phenylalanine main-chain amide and carbonyl form
hydrogen bonds to the FXI residue Asn106 main-chain carbonyl and
side chain nitrogen, respectively. The peptide glutamate residue side
chain forms a hydrogen bond to the side chain of Asn106.
In addition, we determined the 2.8-A˚ structure of FXI in complex
with peptide P39 from the random screen using a similar protocol.
Clearly identiﬁable electron density was observed for the 8-residue
sequence IYPDFPTD (supplemental Figure 2). The peptide occupies
the same elongated crevice as the laminin peptide, and the
tyrosine aromatic side chain packs into the same minor pocket. At
theC-terminusof theP39 structure, theThr-Asp residues areobserved to
formminor van derWaals contacts with FXI, as shown in Figure 2B-C.
Structure of the HK DFP peptide FXI complex
The FXI complex structure with a 12-mer peptide containing HK
amino acids 582 to 593 was solved to 2.85-A˚ resolution. The HK
peptide HKP was also observed bound to the apple 2 domain, and
the sequence NPISDFPD was successfully identiﬁed in the
electron density (Figure 2D). The DFP motif occupies the same
major pocket as P39 peptide, and the isoleucine side chain fromHKP
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Figure 2. FXI peptide complex structures.Q:22 (A)
Cartoon diagram showing only the apple 2 domain in
white, with laminin LP2 peptide shown as sticks in
orange. Electrostatic and hydrogen bonding interac-
tions are shown as purple dotted lines. Residues
interacting with the peptide are shown as sticks in
green. (B) Charged surface representation of the apple
2 domain (blue is positive, red is negative) bound to the
P39 peptide (orange) shown as sticks. (C) Schematic
diagram illustrating the P39 peptide (purple) bound to
the apple 2 domain, calculated using LIGPLOT
software, with major and minor pockets indicated. (D)
Cartoon diagram of the apple 2 domain in white, with
bound HK peptide in blue shown as sticks. (E) Schematic
diagram illustrating HK peptide (purple) bound to the
apple 2 domain, calculated using LIGPLOT. (F) Super-
position of the FXI-P39 and FXI-HKP peptide apple 2
domain structures. The apple 2 domain is shown as a
cartoon in white for the FXI-P39 structure, and the P39
and HKP peptides are shown as sticks in orange and
purple, respectively.
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forms an equivalent packing interaction to the tyrosine side chain
from P39, contacting the FXI apple 2 domain minor pocket
(Figure 2E).
Figure 2F illustrates superposition of the FXI-P39 and FXI-HKP
structures, revealing differences between IxDFP and YxDFP, whereby
the DFP Phe contact with the FXI apple 2 domain major pocket
is identical; however, there is some ﬂexibility in the positioning of the
N-terminal amino acids contacting the minor pocket. The P39 peptide
tyrosine main-chain backbone amide forms a hydrogen bond to the
main-chain carbonyl of FXI Asn140, which does not occur in the HKP
complex. In contrast, both the native FXI structure and the HKP
complex have a water molecule bound to the side chain of Asn140. In
the HKP complex, this water molecule is also coordinated by the DFP
aspartate side chain, whereas in the laminin and P39 complex structure,
there is no bound water present and the DFP aspartate side chain is
slightly reoriented, forming an interaction with the Asn106 side chain.
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Figure 3. HK amino acid sequence and interaction with FXI. (A) The HK C-terminal domain 6 amino acid sequence alignment derived from the National Center for
Biotechnology Information HOMOLOGENE server for different species is indicated. Conserved residues across .50% of the sequences are shaded black (highly conserved)
or gray (weak conservation) with the program BOXSHADE. Peptides P27 and P31 from the random screen that match sequences within HK domain 6 are shown aligned.
Dashed lines represent the sequence of synthetic peptides HKP and HKC. + indicates missense mutation Ile563Thr, located directly N-terminal to the HK ISDFP sequenceQ:23 .
Plots of SPR sensorgrams measured in response units (RU) illustrate peptide P39 (B) and HKP (C) binding to immobilized FXI, and FXI binding to immobilized HK (D).
(E) Binding of the HKC peptide to immobilized FXI.
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Biological significance of the FXI-HKP complex structure
The FXI-HKP structure is supported by previous data: biochemical
characterization of the interaction between FXI and HK has localized
binding to the C-terminal portion of theHKdomain 6, spanning at least
58 amino acids (HK residues 556-613) and containing the HKP
sequence.25 An alignment of the HK C-terminal region of domain 6
sequences across several species shows that the ISDFP sequence in
HKP is well conserved (Figure 3A). Amino acid substitutions in the
region surrounding ISDFP show similarities to the conserved features
identiﬁed in the random peptide screen. In common with the FXI
binding peptide sequences from the random screen, (1) the aspartate
from the HKP DFP is absolutely conserved, (2) a proline residue is
present directly N-terminal to the DFP in elephant and mole rat
sequences, (3) a lysine residue is present 4 amino acids N-terminal to
the DFP in cow, mole rat, and mouse, and (4) the mole rat IPDLP
sequence is similar to the screen peptide 7, which has sequence FPDLP
(supplemental Figure 1). One signiﬁcant difference with the random
peptide screen is that the HK sequences have a conserved isoleucine
residue occurring 2 amino acids N-terminal to the DFP that is not
substituted to F/Y/W/H in any species.
Previously, it had been shown that monoclonal antibodies against
the FXI apple 2 domain can inhibit the FXI-HK interaction, with
binding constants in the low nanomolar range.26,27 To examine the
interaction of FXI with HK and peptide P39, we developed an SPR
assay (see “Methods”). Using this assay, the P39 peptide and the HKP
peptide bound to immobilized FXI with a KD of 320mMand 324mM,
respectively, which is similar to the 150mMvalue previously reported
for a 13-mer peptide25 from the HK sequence (Figure 3B,C). The
binding of FXI to full-length HK resulted in a KD of;0.3 nM, which
differs signiﬁcantly from the published value of 69 nM that was
measured for the isolated HK light-chain fragment in a solution-based
assay.25 Furthermore, using the same SPR assay, the homologous
protein PK binding to HK resulted in a KD of 18 nM (data not shown),
which is in excellent agreement with the published value of 12 nM
measuring the PK interaction with the HK light-chain fragment.25
Because previous data have described that at least 58 amino acids
from theHK domain 6 contribute to FXI binding,25 we examined these
amino acid stretches for furthermatches with the FXI binding peptides.
This revealed a sequence similaritywith theDFDFXI binding peptides
in the far C-terminal region of HK (Figure 3A shows the peptide P31
sequence aligned). To test whether this sequence binds FXI, we
synthesized a peptide spanning the C-terminal residues 607 to 626 of
HK (HKC) and, in anSPRexperiment, recorded speciﬁc bindingwith a
measured KD of 90 mM.
The FXI “saucer sections” organize DFP peptides onto the
same surface
The structure of the HKP peptide bound to the apple 2 domain in the
FXI saucer section is shown in Figure 4A. Two FXI monomers
assemble into a disulﬁde-linked dimer through the apple 4 domain;
Figure 4B shows that the 2 HKP peptides are organized onto an
opposing surface in relation to the protease domain. The peptides
are facing the dimer axis in an arrangement that effectively localizes
the apple 2 domain binding pockets in the same plane 45 A˚ apart
(Figure 4B). The apple 4 domain dimer interface is offset by an angle
of 90° such that the orientation of the 2 bound HK peptides is
approximately at right angles (Figure 4C; supplemental Video). This
arrangement raises the question as to whether, in the biological
complex, 2 HK polypeptides bind FXI using both apple 2 domains.
Early studies isolated the tightly bound FXI-HK complex from
plasma, describing a complex of 380 kDa characterized by gel
ﬁltration.9 The disulﬁde-linked dimeric nature of FXI is well
established biochemically and structurally,5 and on gel ﬁltration, it
elutes at;200 kDa,which is the samemolecularweight described by
nonreducing sodium dodecyl sulfate (SDS)–polyacrylamide gel
electrophoresis (PAGE). HK, by comparison, has been previously
reported as both a disulﬁde-linked circular monomer28 and dimer.29,30
We repeated these gel ﬁltration experiments to examine the stoichi-
ometry of binding for theFXI-HKcomplexusing a calibratedSuperdex
200 column. This revealed that FXI elutes close to the expected
molecular weight of the disulﬁde-linked dimer at ;200 kDa
(supplemental Figure 3). Gel ﬁltration of FXI-HK mixtures with
varying ratioa revealed a peak for a complex obtainedwith amolecular
weight of ;400 kDa, consistent with previously published results.9
SDS-PAGE of samples collected from the resulting gel ﬁltration frac-
tions of the FXI-HK complex revealed that both components were
A4
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HKP
HKP HKP
45A
90°
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A3
Figure 4. FXI dimer colocalization of bound HK peptides. (A) Cartoon diagram
of the apple domain saucer section shown in gray, blue, orange, and yellow for the
A1, A2, A3, and A4 domains, respectively. The HK peptide is colored in dark blue and
shown as sticks. (B) The FXI dimer bound to the HK peptide (blue sticks) is shown
with the protease domain (white) and active-site residues (red spheres) for His413,
Asp462, and Ser557. The distance between the HK peptide is indicated as 45 A˚, and
the vertical arrow shows the dimer axis. (C) Surface representation of the FXI dimer,
with each subunit colored the same as in panel AQ:24 , except the protease domain is red.
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present, and nonreducing SDS-PAGE gels revealed FXI and HK
migrating at the same molecular weight of ;200 kDa (supplemental
Figure 3). To quantitate FXI and HK in these experiments, a gel
ﬁltration experiment with a 1:1 molar ratio of FXI and HK was
performed, and samples of the resulting single peak were analyzed by
Edman degradation, conﬁrming the equimolar presence of FXI andHK
polypeptides in the 2:2 FXI-HK 400-kDa complex (supplemental
Table 4). The lower plasma concentration of FXI dimer (0.031 mM)
compared with HK (0.6363 mM) means that the 2:2 complex will be
favored, and the structural data suggest that the 2 domains of HK
domain 6 will be aligned in close proximity (Figure 4C).
FXI binding to laminin and a collagen V–derived DFP peptide
Laminins are large heterotrimeric proteinswitha,b, andg subunits and
forma critical component of the basementmembrane.31 Laminin 111 is
important in development and occurs in the brain, whereas laminin 411
and 511 are abundant in the extracellular matrix of blood vessels and
arteries.31 FXI has not been previously shown to bind proteins from the
extracellular matrix; however, our observation that the FPDFP and
YPDFP motifs are present in laminin prompted us to evaluate the
binding of FXI to human laminin heterotrimers 111, 411, and 511
using SPR. These experiments demonstrated that FXI bound in a
concentration-dependentmanner to laminin 111, 411, and 511withKD
values of 11.1 nM, 9.2 nM, and 8.3 nM, respectively (plots shown in
Figure 5; all KD values were determined using a Hill plot and averaged
from triplicated experiments). We also found that laminin 111 puriﬁed
from a native basement membrane (Engelbreth-Holm-Swarm murine
sarcomabasementmembrane; Sigma) boundFXI in a similar fashion to
the recombinant laminins, with a KD of 18.8 nM (data not shown).
The HPDFP motif occurs in the C-terminal noncollagenous (NC)
domains of collagen V and XI a1 chains (termed a1[V]) and does not
occur in the ﬁbrillar regions. To test whether a peptide derived from
the a1(V) sequenc Q:11e could bind FXI, we synthesized the sequence
KDLQLCHPDFPDGE; SPR measurements revealed that this bound
with a KD of 78 mM (Figure 5D).
Discussion
FXI contains 4 apple domains,which aremembers of the plasminogen,
apple, and nematode family of protein folds found in the coagulation
factors plasminogen, FXI, and PK, as well as in parasite cell binding
proteins and hepatocyte growth factor.32 One of the fundamental and
unanswered questions is how these apple domains recognize ligands.32
Here, we report that FXI binds peptides containing the DFPmotif, with
a preference for I/Y/F/W/HxDFP pentapeptides. Three complex crystal
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Figure 5. FXI binding to laminin and a collagen V peptide. Plots of biacore SPR sensorgrams measured in response units (RU) illustrating FXI binding to laminin 111 (A),
laminin 411 (B), or laminin 511 (C) immobilized on a CM5 sensor chip. (D) DFP peptide derived from the collagen V sequence binding to immobilized FXI.
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structures describe examples of I/Y/FxDFP peptides bound to the FXI
apple 2 domain that utilize amajor pocket in the center of theb sheet to
bind the DFP; a minor pocket is occupied by the I/Y/F amino acid side
chain. A second distinct group of FXI binding peptides were identiﬁed
that contained theDFDmotif, and thesewere found tohave similarity to
the C-terminal region of HK.
The data are biologically signiﬁcant, in that an ISDFP pentapeptide
occurs in the amino acid sequence of domain 6 from HK, which is a
known cofactor of FXI. HK acts as a cofactor for FXI zymogen
activation by FXIIa33,34 cleavage, and functional assays have shown
that peptides derived from the HK domain 6 sequence inhibit kaolin-
stimulated coagulation reactions.25 Monoclonal antibodies that bind to
theFXI apple 2 domain have been shown to inhibitHKbinding invitro,
as well as thrombus formation in vivo in animal models of cardiovas-
cular disease.27 In addition to studies in animals, global genetic linkage
analysis of mutations in humans has identiﬁed a common HK variant
located in domain 6 that is linked to greater susceptibility to deep vein
thrombosis and changes in coagulation.35 This missense mutation
Ile563Thr is located directly N-terminal to the HK ISDFP sequence
(highlighted in Figure 3A as a star). Directly C-terminal to the HK
ISDFP sequence is the Cys596 residue, which is implicated in forming
a disulﬁde bondQ:12 with Cys10 from the HK N-terminus, although the
complete disulﬁdebondinghas been reported previouslyonly for splice
variant low-molecular-weight kininogen,36 and not forHK.The overall
3-dimensional structure of the HK domain 6 is unknown, and there are
no homologous proteins in the database to allow molecular modeling.
We identiﬁed theHPDFP sequence in theC-terminalNCdomain of
collagenV. This sequence occurs in thea1(V) chain, and collagenV is
normally present within the interiors of collagen ﬁbers asa1(V)2a2(V)
heterotrimers. Upon secretion, the collagen V C-terminal NC domains
are cleaved off and secreted into the extracellular space.37 Excessive
amounts of a1(V) chains have been shown to be deposited in athero-
sclerotic lesions, although it is unknown whether the C-terminal NC
domains are also deposited38,39
FPDFP and YRDFP pentapeptide sequences occur within the
extracellular matrix protein laminin, and we demonstrated binding of
FXI to native and recombinant laminin heterotrimers. There is in-
creasing evidence of the importance of laminins in plasma coagulation
and thrombus formation, and the interaction between platelet integrins
and laminins has been well characterized.40,41 Efﬁcient coagulation
factor cleavage reactions typically take place only on a designated sur-
face, and vitamin K–dependent coagulation factors have an N-terminal
Gla domain that is capable of binding directly to negatively charged
phospholipids present in activated platelets to fulﬁll this purpose.
Laminin has been previously shown to provide a surface that can
promote plasma coagulation and thrombus formation in the absence of
platelets.42 HK and coagulation FXII (which activates FXI) have both
previously been reported to bind laminin.43,44 It is notable that the
substrate of FXIa (ie, FIX) binds the basement membrane through
a well-characterized interaction with collagen IV,45 and the interaction
we observe for FXI with laminin may be important for colocalization
of coagulation factors from the intrinsic pathway to sites in the
extracellular matrix.
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